Subscribe To
VYNT / Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value
VYNT News
By Proactive Investors
May 12, 2023
Vyant Bio to pursue listing on OTC Pink Open Market
Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist more_horizontal
By Proactive Investors
February 3, 2023
Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives
Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agree more_horizontal
By Proactive Investors
January 4, 2023
Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value
Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on more_horizontal
By Seeking Alpha
November 17, 2022
Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript
Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Office more_horizontal
By Proactive Investors
November 15, 2022
Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show
Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at leas more_horizontal
By Proactive Investors
November 3, 2022
Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million
Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, a more_horizontal
By Proactive Investors
August 23, 2022
Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year
Vyant Bio (NASDAQ:VYNT) Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early more_horizontal
By Seeking Alpha
August 22, 2022
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript
Vyant Bio, Inc. (NASDAQ:VYNT ) Q2 2022 Results Earnings Conference Call August 22, 2022 4:30 PM ET Company Participants Jay Roberts - President and Ch more_horizontal